Premium
AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES
Author(s) -
Flinn I.W.,
Davids M.S.,
Hillmen P.,
Montillo M.,
Delgado J.,
Kuss B.J.,
Tam C.S.,
Jäger U.,
Ghia P.,
Stilgenbauer S.,
Lustgarten S.,
Weaver D.T.,
Youssoufian H.,
Cymbalista F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.29_2630
Subject(s) - medicine , neutropenia , gastroenterology , febrile neutropenia , clinical endpoint , diarrhea , ofatumumab , population , chronic lymphocytic leukemia , randomized controlled trial , surgery , leukemia , toxicity , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom